Please wait a minute...
European Journal of Gynaecological Oncology  2019, Vol. 40 Issue (4): 547-550    DOI: 10.12892/ejgo4514.2019
Original Research Previous articles | Next articles
Determination of miR-193b rs30236 single nucleotide polymorphism in ovarian cancer patients
B. Soltész1, J. Lukács2, A. Penyige1, R. Póka2, B. Nagy1, *()
1 Department of Human Genetics, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
2 Institute of Obstetrics and Gynecology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
Download:  PDF(462KB)  ( 212 ) Full text   ( 6 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Background: Single nucleotide polymorphism (SNP) is the most common form of genetic variability. The miR-193b was connected to several types of tumors and also with occurrence of resistance to chemotherapy. This investigation aimed to determine miR-193b rs30236 polymorphism in ovarian cancer patients and controls. The authors performed bioinformatics analysis to discover the target genes of miR-193b. Materials and Methods: Eighty-six ovarian cancer patients and 102 matched controls were included in the study. Blood samples were drown into EDTA tubes and DNA was isolated by silica adsorption method. Mir-193b rs30236C/T polymorphism was determined by melting curve analysis. Chi-square test was used for statistical evaluation of the data. MiRTargetLink was used for determination of the has-miR-193b-3p microRNA target genes. Results: Based on melting curve analysis of miR-193b rs30236, the authors found 30.24% T allele frequency in the patients’ group, and 35.78% in the control group (p = 0.2549). They detected CC genotype in 39.22%, CT genotype in 50.00%, and TT genotype in 10.78% of controls, while they occurred in 45.35%, 48.84%, and 5.81% of the patients (p = 0.4096), respectively. The most important target genes of miR-193b are cyclin D1 (CCND1), estrogen receptor (ESR1), plasminogen activator (PLAU), prolin rich acidic protein (PRAP1), and myeloid leukemia sequence (MCL1). Conclusions: The miR-193b has effect on the expression of several genes. The rs30236 polymorphism has not been studied in ovarian cancer patients, yet. The authors did not find significant difference in allele and genotype difference in patients and controls. To discover the exact role and suitability of this SNP for use as biomarker in the ovarian cancer prior to chemotherapy, more detailed studies are needed.
Key words:  miRNA      miR-193b      SNP      Gene expression      Ovarian cancer      Melting curve analysis     
Published:  10 August 2019     
*Corresponding Author(s):  B. NAGY     E-mail:  nagy.balint@med.unideb.hu

Cite this article: 

B. Soltész, J. Lukács, A. Penyige, R. Póka, B. Nagy. Determination of miR-193b rs30236 single nucleotide polymorphism in ovarian cancer patients. European Journal of Gynaecological Oncology, 2019, 40(4): 547-550.

URL: 

https://ejgo.imrpress.com/EN/10.12892/ejgo4514.2019     OR     https://ejgo.imrpress.com/EN/Y2019/V40/I4/547

[1] Buse Güler, Merve Çamlıbel, Samiye Mete. What Do Relatives of Turkish Women with Ovarian Cancer Share on Websites? : A Qualitative Research[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 732-738.
[2] Yudi Mulyana Hidayat, Gatot Nyarumenteng Adhipurnawan Winarno, Maringan Diapari Lumban Tobing, Arieff Kustiandi, Kemala Isnainiasih Mantilidewi, Sofie Rifayani Krisnadi. The Role of Akt2 and CA-125 Serum Levels as Predictors for Successful Cytoreduction in Epithelial Ovarian Cancer Surgery[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 739-744.
[3] Lingyun Zhai, Lixin Zeng, Hongru Jiang, Wei Li. Effects of a cyclooxygenase-1-selective inhibitor in combination with taxol or cisplatin on cyclin D1, apoptosis, and vascular endothelial growth factor in a xenograft model of ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 779-784.
[4] Qinglian Ma, Wenjie Yan, Jing Yang, Haiyan Wang, Weixiang Wang, Minghui Dong. Functional interpretation of ovarian cancer in correlation with ISGF3 expression pattern[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 769-773.
[5] Silvia Ortega, José Angel Mínguez, José Manuel Aramendía, Marta Santisteban, Fernando Martinez-Regueira, Pablo Martí-Cruchaga, Juan Luis Alcázar, Matías Jurado. The impact of secondary cytoreductive surgery on survival in first recurrence of platinum sensitive epithelial ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 523-530.
[6] Jae Hong Sang, Soo-Ho Chung. Is it enough in ovarian cancer staging surgery to laparoscopic surgery? Comparison of surgical methods[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 541-544.
[7] Sigit Purbadi, Gregorius Tanamas, Lisa Novianti. Advanced stage ovarian cancer survival in Jakarta[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 587-590.
[8] Gen-Hai Zhu, Kang Wang, Lan Hong, Xin-Hui Fu, Fu-Jin Liu, Hai-Yan Huang. Safety and efficacy of fertility-sparing surgery for an orthotopic xenograft model of epithelial ovarian cancer in nude mice[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 609-616.
[9] Xifang Lv, Amanguli, Ping Yang. The role of sodium hydrosulfide in the proliferation and apoptosis of exogenous SB203580 pre-treated human ovarian cancer cells[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 622-628.
[10] Chenchen Zhu, Hanyuan Liu, Zhen Shen, Yanhu Xie, Tianjiao Zhang, Björn Nashan, Dabao Wu, Ying Zhou. Treatment and survival outcomes from epithelial ovarian cancer in women aged 65 years or older[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 415-421.
[11] F. Oyama, Y. Asano, H. Shimoda, K. Horie, J. Watanabe, Y. Yokoayama. Morphological analysis of peritoneal dissemination of ovarian cancer based on levels of carbonyl reductase 1 expression[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 352-360.
[12] C.J. Heesterbeek, A.M. Thijs, R.H.M. Hermans, D. Boll, G.-J. Creemers. Bevacizumab in combination with metronomic oral cyclophosphamide: an effective and well-tolerated treatment for patients with recurrent ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 364-367.
[13] S.R Oh, J.-W. Park. Is the Risk of Malignancy Index a predictive tool for preoperative differentiation between borderline ovarian tumor and ovarian cancer?[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 368-374.
[14] T. Shoji, E. Takatori, M. Kagabu, M. Futagami, Y. Yokoyama, H. Tokunaga, N. Yaegashi, T. Ohta, T. Watanabe, T Sugiyama. Relationship between usefulness of irinotecan and pegylated liposomal doxorubicin therapy and the UGT1A1 genotype in patients with recurrent ovarian cancer (TGCU 104 study)[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 380-385.
[15] Emine Karabuk, Burak Karadag, Ceyda Karadag, M. Faruk Kose, M. Murat Naki, E. Nilufer Guler. The outcomes of fertility sparing surgery in epithelial ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 391-395.
No Suggested Reading articles found!